Attempts have been made with the anti-CTLA-4 antibody ipilimumab plus radiation therapy, ADT and other checkpoint inhibitors (anti-PD-1), although with limited enhanced treatment effects in prostate cancer [8]. This evidence concerns the gene CTLA4 and prostate carcinoma.